Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients

This study has been completed.
Sponsor:
Collaborators:
Hoffmann-La Roche
GlaxoSmithKline
Information provided by:
Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT00226447
First received: September 23, 2005
Last updated: October 23, 2008
Last verified: October 2008
  Purpose

The aim is to investigate the best treatment regime of PEG-Intron A and lamivudine combination in terms of viral clearance in chronic hepatitis B patients.


Condition Intervention Phase
Chronic Hepatitis B
Drug: Pegylated Interferon
Drug: Lamivudine
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study on the Viral Kinetics of Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in HBeAg Positive Chronic Hepatitis B

Resource links provided by NLM:


Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:
  • HBV DNA reduction at week 52

Secondary Outcome Measures:
  • Normalization of ALT & negative HBV DNA at EOT, negative HBV DNA at EOT & 24 weeks after cessation of treatment, normalization of ALT at the end of treatment and 24 weeks after the cessation of treatment, Safety of treatment

Estimated Enrollment: 30
Study Start Date: December 2002
Study Completion Date: July 2006
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Detailed Description:

Chronic hepatitis B is a major cause of mortality and morbidity in Hong Kong and most Southeast Asian countries. The efficacy interferon-alfa (IFN-alfa) or lamivudine monotherapy is far from satisfactory with approximately 20% sustained viral response. Extended use of lamivudine is associated with the emergence of drug resistance mutants. As interferon is an immune modulator and lamivudine directly suppresses viral replication, it is therefore logical to combine the 2 drugs for more efficient viral clearance.

Previous studies on IFN-alfa and lamivudine combination treatment of chronic hepatitis B showed marginal benefit over lamivudine monotherapy. In these studies, lamivudine was either started 8 weeks prior to IFN-alfa or simultaneous with IFN-alfa. Recently, we have performed a study comparing the efficacy of polyethylene glycol-interferon alfa-2b (PEG-Intron A) and lamivudine versus lamivudine monotherapy for 1 year in the treatment of chronic hepatitis B. In our protocol, PEG-Intron A is started 8 weeks before the commencement of lamivudine, and PEG-Intron A is given for 32 weeks while lamivudine is given for a total of 52 weeks. Our published results suggested PEG-Intron A and lamivudine combination treatment is far superior to lamivudine monotherapy (end of treatment virological response 92% vs 20%, p=0.0015). We are not certain whether the benefit of PEG-Intron A and lamivudine combination in our study is due to our staggered regime, the superiority of PEG-Intron A over IFN-alfa, or both. The aim of this study is to investigate the best treatment regime of PEG-Intron A and lamivudine combination in terms of viral clearance.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • HBsAg positive for at least 6 months prior to screening
  • Serum HBV-DNA > 10^6 copies per ml at screening
  • Serum HBeAg positive at screening
  • Abnormal ALT (1.3-10x upper limit normal) within one month prior to entry
  • Compensated liver disease with the following minimum criteria:

    1. Hemoglobin within range & not less than 10% from lower normal limit
    2. WBC >= 4,000/mm3
    3. Platelets >= 100,000/mm3
    4. Bilirubin normal (except for Gilbert's disease).
    5. Albumin stable and normal
  • Serum creatinine normal or not more than 10% above the upper normal limit
  • Thyroid Stimulating Hormone (TSH) within normal limits (Patients requiring medication to maintain TSH levels in the normal range are eligible if all other inclusion/exclusion criteria are met.)
  • Alfa-fetoprotein in normal range (obtained within the previous year, or if elevated and < 500 ng/ml with a negative ultrasound for hepatocellular carcinoma at screening).
  • Written informed consent

Exclusion Criteria:

  • Co-infection with hepatitis C virus and/or HIV
  • Evidence or history of decompensated liver disease

    1. Child's B cirrhosis
    2. Ascites, bleeding varices, spontaneous encephalopathy
    3. Hypersplenism (hemoglobin, white cell count, platelet outside inclusion criteria)
    4. Coagulopathy (PT > 13 sec)
  • Any known pre-existing medical condition that could interfere with the patient's participation in and completion of the treatment such as:
  • Pre-existing psychiatric condition, especially severe depression, or a history of severe psychiatric disorder.
  • Patients on anti-depressant therapy are excluded
  • CNS trauma or active seizure disorders requiring medication
  • Poorly controlled diabetes mellitus
  • Immunologically mediated disease (e.g., inflammatory bowel disease (Crohn's disease, ulcerative colitis, idiopathic thrombocytopenic purpura, lupus erythematous, autoimmune hemolytic anemia, scleroderma, severe psoriasis, rheumatoid arthritis).
  • Clinical gout
  • ANA > 1:320
  • documentation that women of childbearing potential are using contraception. A serum pregnancy test obtained within two weeks prior to initiation of treatment must be negative. Female patients must not be breast feeding.
  • Any known history of hypersensitivity to nucleoside analogues or interferon
  • Previous use of interferon, lamivudine, immunosuppressive drugs or corticosteroid
  • Subjects with clinically significant retinal abnormality
  • Substance abuse, such as alcohol (>80 g/day), iv drugs and inhaled drugs. If the subject has a history of substance abuse, to be considered for inclusion into the protocol, the subject must have abstained from using the abused substance for at least 2 years. Subjects receiving methadone within the past 2 years are also excluded.
  • Subjects not willing to be counseled/abstain from the consumption of alcohol
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00226447

Locations
China
Cheng Suen Man Shook Hepatitis Center, Institute of Digestive Disease, The Chinese University of Hong Kong, Prince of Wales Hospital
Hong Kong SAR, China
Sponsors and Collaborators
Chinese University of Hong Kong
Hoffmann-La Roche
GlaxoSmithKline
Investigators
Principal Investigator: Henry LY Chan, MD Chinese University of Hong Kong
  More Information

Publications:

Responsible Party: Professor LY Chan, Chinese University of Hong Kong
ClinicalTrials.gov Identifier: NCT00226447     History of Changes
Other Study ID Numbers: P03227
Study First Received: September 23, 2005
Last Updated: October 23, 2008
Health Authority: Hong Kong: Department of Health

Keywords provided by Chinese University of Hong Kong:
Chronic Hepatitis B
Pegylated Interferon
Lamivudine

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
DNA Virus Infections
Digestive System Diseases
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interferons
Lamivudine
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 27, 2014